ClinicalTrials.gg
RecruitingNCT05553353Updated Jan 14, 2026

Dosing rTMS for Depression Post-SCI

An interventional study of repetitive transcranial magnetic stimulation--Active and repetitive transcranial magnetic stimulation--Sham in Spinal Cord Injuries, Depression and Depressive Disorder, Major, sponsored by VA Office of Research and Development. Recruiting at 1 site in United States. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-01-14.

Sponsored by VA Office of Research and Development · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2025; still recruiting 1 year 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 76 studies in Spinal Cord Injuries by VA Office of Research and Development — 17 open to participants now, 18 under way, 1 of them phase 3. Spinal Cord Injuries · VA Office of Research and Development.

Planned enrollment
28th of 69
24 · median 20
Started
2025
with 1 other
No phase
52 of 76
14 open now
Primary completion
2027-04
later than 4 of 17 live
Registered
62nd of 76
by date

Among the 76 studies in Spinal Cord Injuries by VA Office of Research and Development, this one is the 28th largest by planned enrollment of the 69 interventional ones that give a count, is one of 2 that started in 2025, is one of 52 with no phase, reaches primary completion later than 4 of the 17 other live ones, and was the 62nd registered.

Spinal Cord Injuries

2,032 studies on the registry are indexed under Spinal Cord Injuries; 542 are open to participants now.

Browse Spinal Cord Injuries studies →

Open to participants now

17 of the 76 studies in Spinal Cord Injuries by VA Office of Research and Development are open now, in 1 country. Recruiting first, the newest first:

11 more — sign in →

By country, each count listing its studies:

All 17 open studies →

Where they have run

Who these studies take

Of the 374 Spinal Cord Injuries studies recruiting now, 167 (45%) set no upper age limit and 156 (42%) stop at 75 or younger; 40 take children under 18; 52 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 76 studies in Spinal Cord Injuries by VA Office of Research and Development, or all of them as a file.
02

Study summary

Depression is a leading cause of disability worldwide and is more commonly seen in individual's post-spinal cord injury (SCI) than in the general population. Depression post-SCI impacts an individuals' quality of life and recovery. It has been reported that among Veterans with an SCI, those without depression live longer than those with depression. Thus, depression must be treated appropriately. Repetitive transcranial magnetic stimulation (rTMS) is an FDA-approved treatment for depression, but dosing is based on a motor response or movement in the thumb. Over half of individuals with SCI have some degree of arm or hand impairment, so these individuals might not be eligible for rTMS, or they may receive the wrong dose. This study proposes clinical trial in individuals with depression post-SCI to assess the anti-depressant effect of a novel technique to dose rTMS that does not require a motor response in the thumb. By gaining a better understanding of the application of rTMS for depression post-SCI, the investigators aim to advance the rehabilitative care of Veterans.

Read the detailed description

Depression is a leading cause of disability worldwide and is one of the most prevalent neuropsychiatric manifestations following spinal cord injury (SCI). Based on an estimated 42,000 Veterans having an SCI1 and an estimated prevalence of depression among Veterans post-SCI of 19-28%, nearly 12,000 Veterans with SCI have comorbid depression at any time. The burden of depression post-SCI is significant, as it can impact quality of life and is associated with increased healthcare utilization and higher mortality. As noted by the updated Clinical Practice Guidelines from the Paralyzed Veterans of America, treating depression is essential, but further research is needed specifically within the SCI population to help formulate stronger evidence-based guidelines.

Repetitive transcranial magnetic stimulation (rTMS), a type of non-invasive brain stimulation, is an FDA-approved treatment option for major depressive disorder (MDD) that is utilized throughout the Veterans Affairs (VA) health system. However, to date, no published studies have examined its effectiveness post-SCI. A critical challenge for widespread administration of rTMS for depression post-SCI is dosing, as the resting motor threshold (rMT), a motor response to transcranial magnetic stimulation (TMS), of the right abductor pollicis brevis (APB) is used to dose rTMS. Approximately 60% of the SCI population has incomplete or complete tetraplegia, indicating some degree of upper extremity (UE) impairment, making rMT not reliably attainable. Thus, it is plausible to conclude that over half the SCI population could be excluded from receiving rTMS treatment for depression or may receive an improper dose, impacting its safety and effectiveness. This represents a major gap in the field of SCI rehabilitation in that a large portion of individuals with SCI have concurrent MDD. As such, evidence-based treatment options are necessary to address the needs of this large clinical cohort, thereby improving the lives of these Veterans, their caregivers, and their families.

This study will examine the potential of rTMS, dosed by reverse-calculation electric-field modeling, to improve depressive symptoms in individuals with MDD post-SCI via a randomized, 2-arm, sham-controlled pilot clinical trial. Over four years, twenty-four individual post-SCI with MDD will be enrolled and randomized to receive 6 weeks (5 sessions/week) of either active or sham rTMS treatment. Using an unbalanced design, a quarter of the sample (n=6) randomized to the sham group and the remainder (n=18) randomized to receive active rTMS. Dosing parameters will follow the FDA-approved protocol of 3,000 pulses/session at 10Hz, and intensity will be determined by reverse-calculation electric-field modeling. The primary outcome measure for this study will be the Hamilton Rating Scale for Depression-17. Participants will also complete a 12- and 24-week post-intervention follow-up assessments. It is hypothesized that rTMS treatment dosed using reverse-calculation electric-field modeling will result in a moderate between-group effect size favoring the anti-depressant benefits of rTMS treatment (vs. sham).

In addition to its established anti-depressive effects, rTMS has also been shown to improve patient-reported outcomes such as quality of life and depression-related disability. An extremely exciting possibility is that effective treatment of MDD results in a virtuous cycle whereby reducing depression concomitantly facilitates improvements in other psychosocial domains. The second aim seeks to explore this possibility by determining the extent to which improvements in depressive symptoms are associated with changes in quality of life and participation in Veterans post-SCI with MDD. This trial is an essential step toward optimizing SCI rehabilitation, while simultaneously providing a unique opportunity to study the effects of depression on psychosocial responses to rehabilitation.

The data generated could inform the development of additional interventions focused on neuromodulation to improve function and quality of life for individuals following SCI and other clinical cohorts with upper extremity motor impairment, (e.g., traumatic brain injury, multiple sclerosis, amputees) who otherwise may not be able to benefit from the anti-depressant effects of rTMS treatment.

03

Conditions studied

  • Spinal Cord Injuries
  • Depression
  • Depressive Disorder, Major

Keywords

  • Spinal Cord Injuries
  • Depression
  • Depressive Disorder, Major
  • Transcranial Magnetic Stimulation
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • cervical or thoracic spinal cord injury at least 6 months prior with AIS A, B, C, or D;
  • 18 - 60 years of age;
  • major depressive disorder, as identified by Structured Clinical Interview for ;
  • Hamilton Depression Rating Scale-17 score > 18;
  • not taking antidepressant medications or no change in doses of psychotropic medication(s) for at least 4 weeks before the study (6 weeks if newly initiated medication)

Exclusion criteria

Exclusion Criteria:

  • concomitant neurologic diseases/disorders or dementia;
  • cognitive impairment ( \<17);
  • history of psychosis or other Axis I disorder that is primary;
  • positive screen for bipolar disorder through the Mini-International Neuropsychiatric Interview;
  • history of claustrophobia;
  • \<1 year;
  • electronic or metallic implants (i.e., metal in the head, cochlear implant, or pacemaker;
  • history of seizures or currently prescribed anti-seizure medications;
  • taking medication that increases the risk of seizures;
  • pregnancy as identified through a positive urine pregnancy test;
  • Hamilton Depression Rating Scale-17 question #3 regarding suicide: >2 or suicide attempt within the previous two years;
  • inability to (University of California, San Diego Brief Assessment of Capacity to Consent) or declined to give .
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    Active rTMS

    Active repetitive transcranial magnetic stimulation (rTMS) that will be administered 5 days/week for 6 weeks. Intensity will be individualized based on reverse-calculation electric-field modeling.

    Device: repetitive transcranial magnetic stimulation--Active

  • Sham comparator
    Sham rTMS

    Sham repetitive transcranial magnetic stimulation (rTMS) that will be administered 5 days/week for 6 weeks. Intensity will be individualized based on reverse-calculation electric-field modeling, but a sham treatment coil will be used; thus, no active treatment will be administered.

    Device: repetitive transcranial magnetic stimulation--Sham

Interventions

  • Devicerepetitive transcranial magnetic stimulation--Active

    Repetitive transcranial magnetic stimulation (rTMS) is a type of non-invasive brain stimulation. An active coil will be used to administer the active rTMS.

    Also known as: rTMS

  • Devicerepetitive transcranial magnetic stimulation--Sham

    Repetitive transcranial magnetic stimulation (rTMS) is a type of non-invasive brain stimulation. A sham coil will be used to administer the sham rTMS.

    Also known as: rTMS

06

What researchers measure

Primary outcomes

  1. Change from baseline in Hamilton Depression Rating Scale-17 (HAM-D17) score immediately post-intervention

    The Hamilton Rating Scale for Depression (HAM-D17) is the most widely used tool to assess the severity of depressive symptoms, once diagnosed, and will be used in this study. The HAM-D17 is a semi-structured interview style questionnaire that asks about one's experience with seventeen different depressive symptoms over the past week. Total HAM-D17 scores range from no depressive symptoms (HAM-D17 = 0-7); mild (HAM-D17 = 8-16), moderate (HAM-D17 = 17-23) or severe depressive symptoms (HAMD-D17 = 24).

    Time frame: Baseline; Following Week 2 of 6-week intervention Following Week 4 of 6-week intervention; Immediately post-intervention; 12-weeks post-intervention; 24-weeks post-intervention

Secondary outcomes

  1. Change from baseline in Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form (Q-LES-Q-SF) at timepoints noted below

    The Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form (Q-LES-Q-SF) is a 16-item questionnaire that asks about the degree of enjoyment and satisfaction in various are of daily functioning, like physical health/activity, mood, work, household duties, school/coursework, leisure time activity, and social relationships. Answers are scored from 1 (very poor) to 5 (very good). It is a valid and reliable measure often used in psychiatric research but has been used in SCI research for neuropathic pain.

    Time frame: Baseline; Following Week 2 of 6-week intervention Following Week 4 of 6-week intervention; Immediately post-intervention; 12-weeks post-intervention; 24-weeks post-intervention

  2. Change from baseline in Sheehan Disability Scale (SDS) Score at timepoints noted below

    Sheehan Disability Scale (SDS): The SDS is a three-item questionnaire that asks how depressive symptoms have impacted work/school, social, and family. It is based on a 10-point scale, where 0 = no disruption to 10 = extreme disruption. This outcome use used in the only randomized control trial for an antidepressant post-SCI.

    Time frame: Baseline; Following Week 2 of 6-week intervention Following Week 4 of 6-week intervention; Immediately post-intervention; 12-weeks post-intervention; 24-weeks post-intervention

  3. Change from baseline in Leisure Time Physical Activity Questionnaire for People with Spinal Cord Injury (LTPAQ-SCI) Score at timepoints noted below

    Leisure Time Physical Activity Questionnaire for People with Spinal Cord Injury (LTPAQ-SCI) is used to assess physical activity levels of individuals with a spinal cord injury. This is a 3-item questionnaire that asks one to report the number of days and minutes of mild, moderate, and heavy-intensity leisure-time physical activity performed over the previous seven days. This is a valid and reliable measure in the SCI population.

    Time frame: Baseline; Following Week 2 of 6-week intervention Following Week 4 of 6-week intervention; Immediately post-intervention; 12-weeks post-intervention; 24-weeks post-intervention

  4. Change from baseline in Craig Handicap Assessment and Reporting Tool - Short Form (CHART-SF) Score at timepoints noted below

    Craig Handicap Assessment and Reporting Tool - Short Form (CHART-SF) assesses how an individual with a disability fulfills roles in six domains, physical independence, cognitive independence, mobility, occupation, social integration, and economic self-sufficiency. It is a valid and reliable measure post-spinal cord injury. The total score ranges from 0 - 600, with a higher score indicating greater independent functioning and higher social and community participation.

    Time frame: Baseline; Following Week 2 of 6-week intervention Following Week 4 of 6-week intervention; Immediately post-intervention; 12-weeks post-intervention; 24-weeks post-intervention

  5. Change from baseline in Reintegration to Normal Living Index (RNL) Score at timepoints noted below

    The Reintegration to Normal Living Index (RNL) is an 11-item questionnaire that assesses one's satisfaction with their performance of mobility, self-care, daily activity, recreational activity, and family roles. The total adjusted score ranging from 0 - 100, with 100 indicating full or complete reintegration.

    Time frame: Baseline; Following Week 2 of 6-week intervention Following Week 4 of 6-week intervention; Immediately post-intervention; 12-weeks post-intervention; 24-weeks post-intervention

  6. Change from baseline Hamilton Depression Rating Scale-17 (HAM-D17) Score at timepoints noted below

    The Hamilton Rating Scale for Depression (HAM-D17) is the most widely used tool to assess the severity of depressive symptoms, once diagnosed, and will be used in this study. The HAM-D17 is a semi-structured interview style questionnaire that asks about one's experience with seventeen different depressive symptoms over the past week. Total HAM-D17 scores range from no depressive symptoms (HAM-D17 = 0-7); mild (HAM-D17 = 8-16), moderate (HAM-D17 = 17-23) or severe depressive symptoms (HAMD-D17 = 24).

    Time frame: Baseline; Following Week 2 of 6-week intervention Following Week 4 of 6-week intervention; 12-weeks post-intervention; 24-weeks post-intervention

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Apr 2027, 24 months after the start.

Of 791 non-industry interventional studies with no phase under Spinal Cord Injuries, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 65. This study's planned 24 months is below that.

Counting every sponsor, half of 840 studies reached it within 36 months; a quarter within 17 and three quarters within 64.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 20, 2022
First posted
Sep 23, 2022
StartActual
Mar 31, 2025
Primary completionEst.
Apr 15, 2027
CompletionEst.
Oct 29, 2027
Last update
Jan 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05553353
Responsible party
Sponsor
First posted
Sep 23, 2022
Start date
Mar 31, 2025
Primary completion
Apr 15, 2027 (estimated)
Completion
Oct 29, 2027 (estimated)
Last update
Jan 14, 2026

Study contacts

Catherine J VanDerwerker, PhD DPT PT
Contact
catherine.vanderwerker@va.gov
(843) 792-5047
Sarah A Jackson, BA MA
Contact
sarah.jackson@va.gov
(843) 789-6700
Catherine J VanDerwerker, PhD DPT PT
principal investigator · Ralph H. Johnson VA Medical Center, Charleston, SC

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion